DEF: Context Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Context Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.

Summary

• Context Therapeutics is seeking stockholder approval for a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-50.
• The primary reason for the reverse stock split is to increase the per share market price to meet Nasdaq's minimum bid price requirement for continued listing.
• The company received a notification from Nasdaq on February 27, 2025, stating it was not in compliance with the minimum bid price rule.
• If the stock price does not reach $1.00 per share for a minimum of ten consecutive business days by August 26, 2025, the company may face delisting.
• The reverse stock split will not change the number of authorized shares or the relative voting power of stockholders.
• No fractional shares will be issued; instead, stockholders will receive cash payments.
• The board has the right to abandon the reverse stock split if it's not in the company's best interest.
• As of April 1, 2025, there were 89,704,194 shares of common stock issued and outstanding.
• The company's board of directors met 11 times during 2024.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split and the company's situation with Nasdaq. While the need for a reverse stock split indicates underlying challenges, the document focuses on the procedural aspects and potential outcomes.

Positives

• A successful reverse stock split could increase the per-share trading price of the common stock, potentially maintaining the Nasdaq listing.
• The company believes that a higher stock price could improve marketability to institutional investors and the investing public.
• The company's 401(k) plan provides a safe harbor minimum contribution equivalent to 3% of employees' eligible compensation.

Negatives

• Reverse stock splits can have a negative perception among investors, analysts, and other stock market participants.
• The stock prices of some companies that have effected reverse stock splits have subsequently declined.
• A reduced number of outstanding shares could adversely affect liquidity.
• The company may not be eligible for any compliance period and would be subject to immediate delisting procedures if it fails to meet the minimum bid price requirement and it has effected a reverse stock split over the prior one-year period.
• The company's board of directors has the right to abandon the reverse stock split if it's not in the company's best interest.

Risks

• There is no guarantee that the reverse stock split will increase the stock price or maintain the Nasdaq listing.
• The market price of the common stock may decrease due to factors unrelated to the reverse stock split.
• The reverse stock split may decrease the liquidity of the common stock and result in higher transaction costs.
• If the Board authorizes the issuance of additional shares of common stock subsequent to the Reverse Stock Split, the dilution to the ownership interest of our existing stockholders may be greater than would occur had the Reverse Stock Split not been effected.

Future Outlook

The company intends to effect the Reverse Stock Split to regain compliance with The Nasdaq Capital Markets minimum bid price requirement, but the Board has reserved the right to abandon the proposed amendment at any time before the amendment of the Amended and Restated Certificate of Incorporation is filed.

Management Comments

• Martin Lehr, Chief Executive Officer, expressed gratitude for stockholders' ongoing support and interest in Context Therapeutics.
• The company believes that providing proxy materials over the Internet increases the ability of stockholders to connect with the information they need, while reducing the environmental impact and cost of the Annual Meeting.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in the biotechnology industry have used this method to regain compliance.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges with Nasdaq compliance have implemented reverse stock splits.
• Comparable companies like ESSA Pharma Inc., also mentioned in the document, are focused on developing novel therapies for the treatment of prostate cancer, indicating a trend in the industry towards specialized cancer treatments.
• The director compensation structure, including cash retainers and equity grants, aligns with industry standards for companies of similar size and stage.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders: The reverse stock split could affect the value and liquidity of their shares.
• Employees: The company's financial stability and future prospects could be impacted by the Nasdaq listing status.
• Investors: The company's ability to raise capital could be affected by its stock price and listing status.

Next Steps

• Stockholder vote on the proposed reverse stock split at the Annual Meeting on June 12, 2025.
• Board decision on whether to implement the reverse stock split and at what ratio, if approved by stockholders.
• Filing of an amendment to the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, if the Board decides to proceed.
• Potential engagement with Nasdaq to demonstrate compliance with listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, compliance, stockholders, common stock, delisting, Context Therapeutics